TherapeuticsMD, Inc. — Director's Dealing 2021

Mar 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-03-04

Reporting Person: Milligan John C.K. IV (President/Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	X	179000	$0.2444	Acquired	1723419	Direct
2021-03-04	Common Stock	F	29964	$1.46	Disposed	1693455	Direct
2020-06-05	Common Stock	G	434814	—	Disposed	0	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Warrant (right to buy)	$0.2444	X	179000	Disposed	2021-03-06	Common Stock (179000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	3582373	Indirect

Footnotes

F1: On March 4, 2021, the reporting person exercised a warrant to purchase 179,000 shares of issuer common stock for $0.2444 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 29,964 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 149,036 shares.

F2: Shares were owned by the Milligan Irrevocable Nonexempt Trust - 2014. These securities were held in a trust for the benefit of the reporting person's spouse and children. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: Shares are owned by John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended.

F4: The warrant vested quarterly in eight equal installments commencing June 30, 2011, becoming fully-vested on March 31, 2013.